Healing of disease by suppressing, inducing and enhancing immune response is termed as immunotherapy. There are two types of immunotherapy namely suppression immunotherapy and activation immunotherapy. Activation immunotherapy is intended to extract or strengthen immune response whereas suppression immunotherapy decrease or restrain the immune response. Cancer immunotherapy is type of activation immunotherapy. Immune system is a compilation of special cells, substances and organs that defend from infections and other diseases, and also safeguard from cancer in different ways. The immune system keeps path of all substances found in body. Foreign substances that immune system does not identify raise an alert, causing the immune system to take action against it. The immune response can demolish everything containing the distant matter, such as microbes or cancer cells.
Request Sample Report @ http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=60647
Immunotherapy earned fame with rising facts about the measures of immune system. Immunotherapy has been increasing in treating several types of cancer rather than other treatment options like radiation and chemotherapy. Immune system shields from infections by wandering all over the body to protect it. The foremost drivers for the increase of immunotherapy medicine market are escalating occurrence of diverse types of cancer and focus on therapies with less side effects and faster drug endorsement processes. The market for cancer immunotherapy is probable to increase with growing population suffering from cancer. Similarly, cancer immunotherapy has been verified to be successful in treating cancer which will accelerate the adoption of cancer immunotherapy for cancer treatment. Conversely, the increasing price of cancer therapies and partial information of cancer immunobiology are the chief factors affect the escalation of immunotherapy drugs market. Further, growing R&D for cancer immunotherapy by researchers will emphasize the growth of cancer immunotherapy market. Scientists have invented a range of new cancer vaccines and monoclonal antibodies for heighten the list of cancer immunotherapy products. Cancer vaccines have been set up to make a privileged income than the common drugs, due to the nature of the sickness and the necessity for these vaccines.
The report provides a comprehensive view on the cancer immunotherapy market we have included a detailed value chain analysis. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cancer immunotherapy market has also been included. The study encompasses a market attractiveness analysis, wherein product segments are benchmarked based on their market size, growth rate and general attractiveness. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period.
The cancer immunotherapy market can be segmented on the basis of products, type and region. Adopted Cell Therapy (ACT), Bispecific Monoclonal Antibodies, PD-1/PD-L1 inhibitors, Interferons IDO Inhibitors, T-Cell Therapy Cytokines, Chimeric Antigen Receptor (CAR), Antibody Drug Conjugates (ADCs), Dendritic Cells and Cytokines are some of the key products of cancer immunotherapy. Depending on type cancer immunotherapy market is bifurcated into, granulocyte macrophage-colony stimulating factor (GM-CSF), adoptive cell transfer, cytokines, immune checkpoint inhibitors, interleukins, monoclonal antibodies, interferon and immunomodulators. Monoclonal antibodies had major contribution in 2014 and estimated to be record fastest growth over the predicted period. Diverse function of monoclonal antibody to bind cancer specific cell to prevent strong cells from infection, would propel the use of monoclonal antibodies. Monoclonal antibodies are synthetic versions of proteins for immune system. Cancer vaccines, also known as cell based therapy, are cancer vaccines that aid to treat cancer by injecting firm substances (cancer vaccines) into the body to activate immune response beside cancer. Non-specific immunotherapy improves the immune system in common way and assist immune system to attack cancer cells.
The report covers forecast and analysis for the cancer immunotherapy market on a global and regional level. The study provides significant data of 2014 along with estimated from 2014 to 2020 based on revenue (USD Million). The report also offers detailed competitive landscape of the global cancer immunotherapy market. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the cancer immunotherapy market based on product segment, type segment and region.
Geographically, cancer immunotherapy market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East Africa. North America dominated the market in 2014 with major share due to increased death and morbidity rates of cancer sufferer. High population of specific gender victims is another important factor for growth of immunotherapy in this region. Furthermore, escalating alertness initiative about cancer by government has lead further number of patients to undergo treatment. Asia Pacific is anticipated to emerge as prominent regional market due to improved healthcare expenses by developing countries in this region.
In order to meet increasing requirement of high populace in Asia Pacific region different companies are striving to fulfill the rising need of immunotherapy. The cancer immunotherapy includes major companies such as F. Hoffmann-La Roche Ltd, Viralytics, Novartis Pharmaceuticals Corporation, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp.
The report segments of the cancer immunotherapy market into:
Cancer Immunotherapy Market: Product Segment Analysis
- Adopted Cell Therapy (ACT)
- Bispecific Monoclonal Antibodies
- PD-1/PD-L1 inhibitors
- Interferons IDO Inhibitors
- T-Cell Therapy Cytokines
- Chimeric Antigen Receptor (CAR)
- Antibody Drug Conjugates (ADCs)
- Dendritic Cells
Cancer Immunotherapy Market: Type Segment Analysis
- Granulocyte macrophage-colony stimulating factor (GM-CSF)
- Adoptive cell transfer
- Immune checkpoint inhibitors
- Monoclonal antibodies
Cancer Immunotherapy Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East & Africa